Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 2Peritoneal Neoplasms 1

Interventions

Specimen Handling 218Magnetic Resonance Spectroscopy 196pembrolizumab 188Carboplatin 163Biopsy 130Cisplatin 129Nivolumab 121Paclitaxel 110Cyclophosphamide 107Radiotherapy 101Gemcitabine 96Dexamethasone 89durvalumab 85atezolizumab 71Rituximab 66Radiation 65Lenalidomide 64Doxorubicin 64Pemetrexed 61Bevacizumab 59Etoposide 56Docetaxel 55olaparib 53Ipilimumab 51Taxes 48Prednisone 48Fluorouracil 47venetoclax 46Cytarabine 46Vincristine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × oregovomab × 90 days × Clear all
NCT04938583 2026-04-06

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

CanariaBio Inc.

Phase 1/2 Active not recruiting
54 enrolled
Gynecologic

Ovarian Neoplasms

NCT05335993 2026-04-03

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

CanariaBio Inc.

Phase 2 Active not recruiting
10 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04498117 2026-04-01

FLORA-5

CanariaBio Inc.

Phase 3 Active not recruiting
615 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05605535 2026-04-01

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

CanariaBio Inc.

Phase 2 Active not recruiting
88 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡